PDCD1 and sarcoma: There has been increased interest in immune regulation as a potential therapeutic avenue in sarcoma treatment, prompting investigation of whether anti-programmed cell death protein 1 (PD-1) or ligand (PD-L1) immune checkpoint inhibitors may have a role in treatment.